The American Academy of Pain Management
The American Academy of Pain Management is an inclusive, interdisciplinary, and integrative organization serving clinicians who treat people with pain through education, setting standards of care, and advocacy.
The American Academy of Pain Management News and Research is made possible, in part, by educational grants from the following sponsers:
Product News and Clinical Trial Results
New Drug Application submitted to FDA for tapentadol extended release tablets for management of chronic pain
December 2, 2009 Source: Johnson & Johnson
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. has submitted a New Drug Application to the U.S. FDA for tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older. Results from three clinical trials show that that tapentadol ER reduces moderate to severe chronic pain compared to placebo and demonstrates long-term safety and tolerability.
[Story]
Victory Pharma, Inc. announces launch of NAPRELAN(R) Dose Card
November 23, 2009 Source: Victory Pharma, Inc
Victory Pharma, Inc. announced today the launch of NAPRELAN® Dose Card. NAPRELAN Dose Card is designed for patients who require relief from mild to moderate pain and inflammation associated with primary dysmenorrhea and acute tendinitis and bursitis. It is also designed for patients suffering from rheumatoid arthritis or osteoarthritis who may be receiving other therapies and need additional anti-inflammatory/analgesic activity for a limited time
[Story]
California minority advocacy groups send letter to Blue Shield of California calling for an end to discriminatory practice that denies patients in pain access to proper medication
November 20, 2009 Source: Healthy African American Families
California minority advocacy groups have recently called on Blue Shield of California to reconsider harmful and discriminatory coverage policies. Their letter to Blue Shield specifically calls for an end to the practice of step therapy, which requires patients to fail on up to five medications before Blue Shield will cover the treatment initially prescribed by a doctor. The California minority advocacy groups say that step therapy disproportionately affects minority and low-income communities in California.
[Story]
FDA approves Qutenza(TM), first and only prescription strength capsaicin product for pain reduction
November 16, 2009 Source: NeurogesX
The U.S. Food and Drug Administration (FDA) has approved Qutenza, a new prescription patch applied to the skin for one hour for reduction of post-shingles nerve pain. Qutenza is the first and only prescription strength capsaicin product. It contains a manmade form of capsaicin, the substance in chili peppers that gives them their heat sensation. After a single one-hour application, directly to the site of pain, Qutenza may reduce post shingles nerve pain for up to 12 weeks.
[Story]